Plain-English translation of NCT04130516 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a first-of-its-kind study testing a new medication called LNS8801 in patients with advanced cancer. Researchers want to find the right dose of this treatment and understand how well it works, both when taken alone and when combined with pembrolizumab (a standard immunotherapy drug). The study will enroll about 200 patients across multiple cancer types.
Many patients with advanced cancer either don't respond well to current treatments or stop responding over time. This medication represents a new approach that researchers hope could help patients whose cancers have progressed despite other therapies, particularly those who can't tolerate or have had severe reactions to standard immunotherapy.
You would take the medication by mouth three times a week or once or twice daily in 21-day treatment cycles, continuing until your cancer progresses or side effects become too severe. Throughout the study, you'll have regular blood tests, imaging scans to check your tumor, and possibly tissue biopsies from accessible tumors. Safety check-ins happen at screening, throughout your participation, and for 30–90 days after you stop taking the medication, depending on whether you're in a combination therapy group.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States